跳至主要内容
临床试验/NCT05311540
NCT05311540已完成4 期

Zinc Supplementation In Very Low Birth Weight Infants-A Randomised Controlled Trial

Zekai Tahir Burak Women's Health Research and Education Hospital1 个研究点 分布在 1 个国家目标入组 195 人开始时间: 2014年3月14日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
195
试验地点
1
主要终点
Incidence of feeding intolerance

研究概览

简要总结

  • Zinc (Zn) is a structural component of human body and is a crucial element for a wide variety of cascades that take place in almost all organ systems.
  • Due to many reasons, preterm infants are generally believed to be naturally in a negative Zn balance during the early periods of life.
  • Regulation of intestinal Zn absorption of preterms is unrelated to infant's Zn status.
  • There still is a lack of knowledge in the possible relation of Zn deficiency and development of NEC and/or feeding intolerance in preterm infants.
  • Even if Zn is studied as an adjunct treatment for neonates and young infants with sepsis and found to reduce treatment failure in these high risk population, data in preventing infectious diseases in preterm infants is still lacking.

详细描述

Background and Objectives: Preterm infants have high zinc (Zn) requirements and are generally believed to be in a negative Zn balance in the early period of life. In this study, we aimed to investigate the effect of high dose Zn supplementation in very low birth weight (VLBW) infants on feeding intolerance and development of mortality and/or morbidities including necrotizing enterocolitis (NEC), late-onset sepsis (LOS).

Methods: This is a prospective randomized trial. VLBW preterm infants with gestational age of <32 weeks were randomly allocated on the seventh day of life to receive extra amount of supplemental zinc along with the enteral feedings or not, besides regular low dose supplementation, from enrollment until discharge. Outcome measures were feeding intolerance, NEC (stage≥2), LOS and mortality.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Prevention
盲法
Double (Participant, Investigator)

盲法说明

An independent physician not involved in the study conducted the random assignment process. The investigators who were blinded to the randomisation process closely followed up the enrolled infants for any evidence of feeding intolerance and/or NEC, late-onset sepsis (LOS), bronchopulmonary dysplasia (BPD), hemodynamically significant patent ductus arteriosus (hsPDA), intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP) along with other possible neonatal morbidities and signs of toxicity or side effects (adverse events)

入排标准

年龄范围
7 Days 至 9 Days(Child)
性别
All
接受健康志愿者

入选标准

  • < 32 weeks gestational age and/or <1500 gr birth weight
  • Born in the study hospital
  • Being able to be fed enterally, even in very small amounts, regardless of the volume of the nutrient

排除标准

  • Major congenital malformations and/or critical congenital heart defects
  • Born in another hospital
  • Severe birth asphyxia
  • Severe sepsis
  • Previous early-onset NEC history
  • Infants on the intervention arm who did not continue Zinc supplementation during the study period
  • Hemodynamically unstability
  • Infants nil per os
  • No consent from the family
  • Death before the 7th day of life

研究组 & 干预措施

Zinc intervention

Experimental

9 mg/day Zinc suspension via og tube along with the routinely used standard multivitamin product containing 3 mg daily dose of Zn, started on day 7 until discharge from hospital

干预措施: Zinc Sulfate (Drug)

结局指标

主要结局

Incidence of feeding intolerance

时间窗: through study completion, an average of 6 months

次要结局

  • Incidence of mortality(through study completion, an average of 6 months)
  • Number of participants with late onset sepsis(through study completion, an average of 6 months)
  • Number of participants with retinopathy of prematurity(through study completion, an average of 6 months)
  • Duration of hospitalization(through study completion, an average of 6 months)
  • Number of participants with necrotising enterocolitis (stage≥2)(through study completion, an average of 6 months)
  • Number of participants with bronchopulmonary dysplasia(through study completion, an average of 6 months)

研究者

发起方
Zekai Tahir Burak Women's Health Research and Education Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Suzan Sahin

Specialist

Zekai Tahir Burak Women's Health Research and Education Hospital

研究点 (1)

Loading locations...

相似试验